India, June 9 -- Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the European Commission or EC has granted approval for AMVUTTRA (vutrisiran) for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication.
The RNA interference or RNAi therapeutics company said the approval broadens the indication for its orphan RNAi therapeutic AMVUTTRA.
AMVUTTRA now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
ATTR-CM is caused by the deposition of misfolded TTR fi...